Wednesday, January 13, 2021 11:13:48 AM
One more point i would like to make is regarding the no of deaths.
At 50% DSMC review we were told 45 deaths were on the trial but it was not broken down to how many deaths were within 28 days. The DSMC came back saying we would like to do a review at 75% and also want to look at Day 42. This is because some of the deaths were post Day 28 and they wanted to include these as well which might push us towards statistical significance.
If there was no separation from Placebo in terms of efficacy, the trial would have been stopped by the DSMC and everyone knows that.
For every trial, there will be a safety and pharmacovigilance group monitoring the SAEs and deaths. They have to report the unblinded case reports of the patients who died to the FDA immediately with in 24 hrs. The FDA will stop the trail if they see anything unusual.
Now we know there are 87 deaths and we know there will be more. It is sad to say this but the more no of deaths, the better chance to have a positive outcome.
Does everyone think Nader gave out that number because someone posted a random question and he was innocently answering that. Wrong. I was asking for this number prior to every conference call which was never answered. Cytodyn/Nader puts it out there only when they want to do it. They know it is very favourable to the drug and that's the reason they gave out that number in the last conference call.
Being said that, all of the above point to Clinical significance. Whether it shows statistical significance is what remains to be seen. the FDA knows that hence the billing codes were given and the open label cohort was initiated.
In this pandemic nobody is looking for statistical significance. For an EUA the FDA needs a well conducted trial with a decent sample size. For CD10 the sample size is very low. We only had 45 subjects with a total symptom score >=4. As Rockleo pointed out, you cannot treat subjects who don't have enough symptoms and expect them to show reduction in symptoms. All treatments which received EUA had completed their trials with enough sample size which we are on the verge of doing.
At 50% DSMC review we were told 45 deaths were on the trial but it was not broken down to how many deaths were within 28 days. The DSMC came back saying we would like to do a review at 75% and also want to look at Day 42. This is because some of the deaths were post Day 28 and they wanted to include these as well which might push us towards statistical significance.
If there was no separation from Placebo in terms of efficacy, the trial would have been stopped by the DSMC and everyone knows that.
For every trial, there will be a safety and pharmacovigilance group monitoring the SAEs and deaths. They have to report the unblinded case reports of the patients who died to the FDA immediately with in 24 hrs. The FDA will stop the trail if they see anything unusual.
Now we know there are 87 deaths and we know there will be more. It is sad to say this but the more no of deaths, the better chance to have a positive outcome.
Does everyone think Nader gave out that number because someone posted a random question and he was innocently answering that. Wrong. I was asking for this number prior to every conference call which was never answered. Cytodyn/Nader puts it out there only when they want to do it. They know it is very favourable to the drug and that's the reason they gave out that number in the last conference call.
Being said that, all of the above point to Clinical significance. Whether it shows statistical significance is what remains to be seen. the FDA knows that hence the billing codes were given and the open label cohort was initiated.
In this pandemic nobody is looking for statistical significance. For an EUA the FDA needs a well conducted trial with a decent sample size. For CD10 the sample size is very low. We only had 45 subjects with a total symptom score >=4. As Rockleo pointed out, you cannot treat subjects who don't have enough symptoms and expect them to show reduction in symptoms. All treatments which received EUA had completed their trials with enough sample size which we are on the verge of doing.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
